BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement

Income StatementCash FlowBalance Sheet

Revenue by Product and Service by Geography

2025-01-01 to 2025-12-31

Swipe to see the full flow
BIOGEN INC. (BIIB) FY2025 Annual P&L / Income StatementIncome statement for 2025-01-01 through 2025-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETProduct revenue, net - Rest of WorldProduct revenue, net - UNITED STATESSubtotal: Multiple Sclerosis - UNITED STATESSubtotal: Multiple Sclerosis - Rest of WorldSubtotal: Rare Disease - Rest of WorldSubtotal: Rare Disease - UNITED STATESTYSABRI product - UNITED STATESSPINRAZA - Rest of WorldTotal Fumarate - UNITED STATESSubtotal: Biosimilars - Rest of WorldTYSABRI product - Rest of WorldVUMERITY - UNITED STATESSPINRAZA - UNITED STATESTotal Fumarate - Rest of WorldTotal Interferon - UNITED STATESTECFIDERA - Rest of WorldAVONEX - UNITED STATESBENEPALI - Rest of WorldTotal Interferon - Rest of WorldCompleted technology for SKYCLARYS (U.S.) - UNITED STATESAVONEX - Rest of WorldCompleted technology for SKYCLARYS (U.S.) - Rest of WorldZURZUVAE - UNITED STATESIMRALDI - Rest of WorldTECFIDERA - UNITED STATESPLEGRIDY - Rest of WorldPLEGRIDY - UNITED STATESVUMERITY - Rest of WorldQALSODY - Rest of WorldFLIXABI - Rest of WorldQALSODY - UNITED STATESBYOOVIZ - Rest of WorldSubtotal: Biosimilars - UNITED STATESBYOOVIZ - UNITED STATESFUMADERM And ADUHELM - Rest of WorldFAMPYRA - Rest of WorldTOFIDENCE - UNITED STATESFUMADERM And ADUHELM - UNITED STATESOther - UNITED STATESOther - Rest of WorldRevenuesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of sales, excluding amortization and impairment of acquired intangible assetsOperating profit (calculated)Operating expenses (calculated)Selling, general and administrativeResearch and developmentAmortization and impairment of acquired intangible assetsAcquired in-process research and development, upfront and milestone expenseCollaboration profit sharing/(loss reimbursement)Impairment of ROU assetRestructuring charges(Gain) loss on fair value remeasurement of contingent considerationOther (income) expense, netIncome before income tax (benefit) expenseNet incomeIncome tax (benefit) expenseRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$23.73 BGross profit (calculated)Gross profit(calculated)$7.49 BOperating profit (calculated)Operating profit(calculated)$1.56 BIncome before income tax (benefit) expenseIncome before incometax (benefit) expense$1.56 BRevenuesRevenues$9.89 BNet incomeNet income$1.29 BProduct revenue, net - Rest of WorldProduct revenue, net - Rest of World$3.57 BOperating expenses (calculated)Operating expenses(calculated)$5.93 BProduct revenue, net - UNITED STATESProduct revenue, net - UNITED STATES$3.55 BIncome tax (benefit) expenseIncome tax(benefit) expense$263.60 MSelling, general and administrativeSelling, general and administrative$2.43 BCost of sales, excluding amortization and impairment of acquired intangible assetsCost of sales$2.40 BSubtotal: Multiple Sclerosis - UNITED STATESSubtotal: MultipleSclerosis - UNITED STATES$2.37 BResearch and developmentResearch and development$1.78 BSubtotal: Multiple Sclerosis - Rest of WorldSubtotal: MultipleSclerosis - Rest of World$1.67 BAmortization and impairment of acquired intangible assetsAmortization and impairmentof acquired intangible assets$515.00 MSubtotal: Rare Disease - Rest of WorldSubtotal: Rare Disease- Rest of World$1.19 BAcquired in-process research and development, upfront and milestone expenseAcquired in-process researchand development, upfrontand milestone expense$471.80 MSubtotal: Rare Disease - UNITED STATESSubtotal: Rare Disease- UNITED STATES$966.20 MComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$13.84 BCollaboration profit sharing/(loss reimbursement)Collaboration profitsharing/(loss reimbursement)$290.20 MTYSABRI product - UNITED STATESTYSABRI - UNITED STATES$965.00 MImpairment of ROU assetImpairment of ROU asset$52.90 MSPINRAZA - Rest of WorldSPINRAZA - Rest of World$921.30 MRestructuring chargesRestructuring charges$48.60 MTotal Fumarate - UNITED STATESTotal Fumarate - UNITED STATES$819.70 M(Gain) loss on fair value remeasurement of contingent consideration(Gain) loss on fairvalue remeasurement ofcontingent consideration$33.60 MSubtotal: Biosimilars - Rest of WorldSubtotal: Biosimilars - Rest of World$715.40 MOther (income) expense, netOther (income) expense, net$305.60 MTYSABRI product - Rest of WorldTYSABRI - Rest of World$700.40 MVUMERITY - UNITED STATESVUMERITY - UNITED STATES$651.20 MSPINRAZA - UNITED STATESSPINRAZA - UNITED STATES$625.50 MTotal Fumarate - Rest of WorldTotal Fumarate - Rest of World$606.80 MTotal Interferon - UNITED STATESTotal Interferon - UNITED STATES$587.80 MTECFIDERA - Rest of WorldTECFIDERA - Rest of World$511.20 MAVONEX - UNITED STATESAVONEX - UNITED STATES$482.90 MBENEPALI - Rest of WorldBENEPALI - Rest of World$453.20 MTotal Interferon - Rest of WorldTotal Interferon - Rest of World$357.80 MCompleted technology for SKYCLARYS (U.S.) - UNITED STATESCompleted technology forSKYCLARYS (U.S.) - UNITED STATES$310.60 MAVONEX - Rest of WorldAVONEX - Rest of World$212.60 MCompleted technology for SKYCLARYS (U.S.) - Rest of WorldCompleted technology forSKYCLARYS (U.S.) - Rest of World$209.90 MZURZUVAE - UNITED STATESZURZUVAE - UNITED STATES$195.10 MIMRALDI - Rest of WorldIMRALDI - Rest of World$190.20 MTECFIDERA - UNITED STATESTECFIDERA - UNITED STATES$168.50 MPLEGRIDY - Rest of WorldPLEGRIDY - Rest of World$145.20 MPLEGRIDY - UNITED STATESPLEGRIDY - UNITED STATES$104.90 MVUMERITY - Rest of WorldVUMERITY - Rest of World$95.60 MQALSODY - Rest of WorldQALSODY - Rest of World$56.80 MFLIXABI - Rest of WorldFLIXABI - Rest of World$52.60 MQALSODY - UNITED STATESQALSODY - UNITED STATES$30.10 MBYOOVIZ - Rest of WorldBYOOVIZ - Rest of World$19.40 MSubtotal: Biosimilars - UNITED STATESSubtotal: Biosimilars - UNITED STATES$13.70 MBYOOVIZ - UNITED STATESBYOOVIZ - UNITED STATES$13.00 MFUMADERM And ADUHELM - Rest of WorldFUMADERM AndADUHELM - Rest of World$1.70 MFAMPYRA - Rest of WorldFAMPYRA(1) - Rest of World$1.40 MTOFIDENCE - UNITED STATESTOFIDENCE - UNITED STATES$700.00 KFUMADERM And ADUHELM - UNITED STATESFUMADERM And ADUHELM- UNITED STATES$400.00 KOther - UNITED STATESOther - UNITED STATES$195.50 MOther - Rest of WorldOther - Rest of World$1.70 M
Chart details

BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues
9,890,600,000 US dollars
Cost of sales, excluding amortization and impairment of acquired intangible assets
2,404,200,000 US dollars
Gross profit (calculated)
7,486,400,000 US dollars
Operating expenses (calculated)
5,929,900,000 US dollars
Operating profit (calculated)
1,556,500,000 US dollars
Other income (expense), net (calculated)
0 US dollars
Income before income tax (benefit) expense
1,556,500,000 US dollars
Income tax (benefit) expense
263,600,000 US dollars
Net income
1,292,900,000 US dollars
AVONEX - UNITED STATES
482,900,000 US dollars
AVONEX - Rest of World
212,600,000 US dollars
BENEPALI - UNITED STATES
0 US dollars
BENEPALI - Rest of World
453,200,000 US dollars
BYOOVIZ - UNITED STATES
13,000,000 US dollars
BYOOVIZ - Rest of World
19,400,000 US dollars
Subtotal: Biosimilars - UNITED STATES
13,700,000 US dollars
Subtotal: Biosimilars - Rest of World
715,400,000 US dollars
FAMPYRA - UNITED STATES
0 US dollars
FAMPYRA - Rest of World
1,400,000 US dollars
FLIXABI - UNITED STATES
0 US dollars
FLIXABI - Rest of World
52,600,000 US dollars
FUMADERM And ADUHELM - UNITED STATES
400,000 US dollars
FUMADERM And ADUHELM - Rest of World
1,700,000 US dollars
Total Fumarate - UNITED STATES
819,700,000 US dollars
Total Fumarate - Rest of World
606,800,000 US dollars
IMRALDI - UNITED STATES
0 US dollars
IMRALDI - Rest of World
190,200,000 US dollars
Total Interferon - UNITED STATES
587,800,000 US dollars
Total Interferon - Rest of World
357,800,000 US dollars
Subtotal: Multiple Sclerosis - UNITED STATES
2,372,500,000 US dollars
Subtotal: Multiple Sclerosis - Rest of World
1,666,400,000 US dollars
Other - UNITED STATES
195,500,000 US dollars
Other - Rest of World
1,700,000 US dollars
PLEGRIDY - UNITED STATES
104,900,000 US dollars
PLEGRIDY - Rest of World
145,200,000 US dollars
QALSODY - UNITED STATES
30,100,000 US dollars
QALSODY - Rest of World
56,800,000 US dollars
Subtotal: Rare Disease - UNITED STATES
966,200,000 US dollars
Subtotal: Rare Disease - Rest of World
1,188,000,000 US dollars
Completed technology for SKYCLARYS (U.S.) - UNITED STATES
310,600,000 US dollars
Completed technology for SKYCLARYS (U.S.) - Rest of World
209,900,000 US dollars
SPINRAZA - UNITED STATES
625,500,000 US dollars
SPINRAZA - Rest of World
921,300,000 US dollars
TECFIDERA - UNITED STATES
168,500,000 US dollars
TECFIDERA - Rest of World
511,200,000 US dollars
TOFIDENCE - UNITED STATES
700,000 US dollars
TOFIDENCE - Rest of World
0 US dollars
TYSABRI product - UNITED STATES
965,000,000 US dollars
TYSABRI product - Rest of World
700,400,000 US dollars
VUMERITY - UNITED STATES
651,200,000 US dollars
VUMERITY - Rest of World
95,600,000 US dollars
ZURZUVAE - UNITED STATES
195,100,000 US dollars
ZURZUVAE - Rest of World
0 US dollars
Product revenue, net - UNITED STATES
3,547,900,000 US dollars
Product revenue, net - Rest of World
3,571,500,000 US dollars
Research and development
1,778,600,000 US dollars
Selling, general and administrative
2,433,600,000 US dollars
Amortization and impairment of acquired intangible assets
515,000,000 US dollars
Gain on sale of priority review voucher, net
0 US dollars
Collaboration profit sharing/(loss reimbursement)
290,200,000 US dollars
Other (income) expense, net
305,600,000 US dollars
(Gain) loss on fair value remeasurement of contingent consideration
33,600,000 US dollars
Restructuring charges
48,600,000 US dollars
Acquired in-process research and development, upfront and milestone expense
471,800,000 US dollars
Impairment of ROU asset
52,900,000 US dollars
Revenue before reconciliation (calculated)
23,730,300,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 13,839,700,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

75.7%

Gross profit / revenue

Operating margin

15.7%

Operating profit / revenue

Cash conversion

170.5%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!